LivDerm

 

LivDerm
Avatar

The Future of Atopic Dermatitis, JAK Inhibitors, and Monoclonal Antibodies: What Are the Differences, Efficacy, and Safety With New Pharmacologics?

By LivDerm FEATURING Lawrence Schachner
February 19, 2021
0 Comments
Login to view comments. Click here to Login
2021 Masters of Pediatric Dermatology
08:08
LivDerm

Welcome Message & Highlights of the South Beach Symposium and Ma…

Feat. L. Schachner
06:30
LivDerm

Telehealth vs. Patient Visits Study Highlights: Elevating the Patien…

Feat. M. Kaufmann
05:01
LivDerm

The Future of Atopic Dermatitis, JAK Inhibitors, and Monoclonal Anti…

Feat. L. Schachner
04:56
LivDerm

COVID-19 & Late Cutaneous Findings in Pediatrics: What Are “COVI…

Feat. A. Maderal
13:10
LivDerm

New Topical Agents for Preteen Acne: What Is the Safety/Efficacy of …

Feat. J. E. Keri
03:04
LivDerm

New Oral Agents for Preteen Acne: Sarecycline Uses, Dosage, and Side…

Feat. J. E. Keri
03:23
LivDerm

Management of Atopic Dermatitis in Infancy/Childhood: A 3 Day Rate o…

Feat. L. Schachner
02:40
LivDerm

Atopic Dermatitis Treatment: The Simple Sliding Scale for Mild to Mo…

Feat. L. Schachner
05:06
LivDerm

Innovation in Acne Treatment: What Are the Latest FDA Approved Drugs…

Feat. L. Schachner
09:35
LivDerm

Atopic Dermatitis & Impetigo Management: How to Effectively Use …

Feat. L. Schachner
05:03
LivDerm

Dermatological Manifestations of COVID-19 in Children: What Are the …

Feat. A. Maderal